

December 8, 2025

Dear All,

Company Name : Delta-Fly Pharma, Inc.
(Code number : 4598 TSE Growth Market)
Inquiries : Kenzo Iizuka, Senior Vice President, R&D
(Contact: <https://www.delta-flypharma.co.jp/en/contactentrance/>)

Update for DFP-10917 related clinical studies

1. All clinical data required for the interim analysis of Phase 3 comparative study of DFP-10917 in R/R AML patients in US has been well prepared and submitted to the Data Safety Management Board (DSMB) for evaluation of clinical efficacy and safety.
2. Expanded study of DFP-14927 in pancreatic cancer patients who failed with Gemcitabine/nab-PTX therapy shall be done objective >25% disease control rate (DCR) at MD Anderson Cancer Center in US.

END